Epigenetic changes in Alzheimer's disease: Decrements in DNA methylation

L.J. Roberts Center for Alzheimer's Research, Sun Health Research Institute, P.O. Box 1278, Sun City, AZ 85372, USA.
Neurobiology of aging (Impact Factor: 4.85). 11/2009; 31(12):2025-37. DOI: 10.1016/j.neurobiolaging.2008.12.005
Source: PubMed

ABSTRACT DNA methylation is a vital component of the epigenetic machinery that orchestrates changes in multiple genes and helps regulate gene expression in all known vertebrates. We evaluated immunoreactivity for two markers of DNA methylation and eight methylation maintenance factors in entorhinal cortex layer II, a region exhibiting substantial Alzheimer's disease (AD) pathology in which expression changes have been reported for a wide variety of genes. We show, for the first time, neuronal immunoreactivity for all 10 of the epigenetic markers and factors, with highly significant decrements in AD cases. These decrements were particularly marked in PHF1/PS396 immunoreactive, neurofibrillary tangle-bearing neurons. In addition, two of the DNA methylation maintenance factors, DNMT1 and MBD2, have been reported also to interact with ribosomal RNAs and ribosome synthesis. Consistent with these findings, DNMT1 and MBD2, as well as p66α, exhibited punctate cytoplasmic immunoreactivity that co-localized with the ribosome markers RPL26 and 5.8s rRNA in ND neurons. By contrast, AD neurons generally lacked such staining, and there was a qualitative decrease in RPL26 and 5.8s rRNA immunoreactivity. Collectively, these findings suggest epigenetic dysfunction in AD-vulnerable neurons.

Download full-text


Available from: Paul D Coleman, Aug 28, 2015
  • Source
    • "Furthermore, some of the DNA methylation deficits in humans were recently found to be specific to brain-regions such as the temporal cortex and the cerebellum (Ladd-Acosta et al., 2013) that are associated with different forms of learning and memory. Similarly, AD is associated with epigenetic alterations in DNA methylation (Mastroeni et al., 2010) and abnormal micro-RNAs expression (Barak et al., 2013). Altered patterns of DNA methylation in immune system and nervous system development genes were found in PTSD (Uddin et al., 2010; Mehta et al., 2013), and schizophrenic patients show decreased genome-wide DNA methylation (Bonsch et al., 2012) and altered DNA demethylation mechanisms (Dong et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: A key characteristic of learning and neural plasticity is state-dependent acquisition dynamics reflected by the non-linear learning curve that links increase in learning with practice. Here we propose that the manner by which epigenetic states of individual cells change during learning contributes to the shape of the neural and behavioral learning curve. We base our suggestion on recent studies showing that epigenetic mechanisms such as DNA methylation, histone acetylation, and RNA-mediated gene regulation are intimately involved in the establishment and maintenance of long-term neural plasticity, reflecting specific learning-histories and influencing future learning. Our model, which is the first to suggest a dynamic molecular account of the shape of the learning curve, leads to several testable predictions regarding the link between epigenetic dynamics at the promoter, gene-network, and neural-network levels. This perspective opens up new avenues for therapeutic interventions in neurological pathologies.
    Frontiers in Integrative Neuroscience 07/2014; 8:55. DOI:10.3389/fnint.2014.00055
  • Source
    • "Human postmortem case-control studies have demonstrated global hypomethylation in the entorhinal cortex of AD subjects [106] and in the temporal neocortex of an AD monozygotic twin relative to the cognitively normal twin [107]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The steady and dramatic increase in the incidence of Alzheimer's disease (AD) and the lack of effective treatments have stimulated the search for strategies to prevent or delay its onset and/or progression. Since the diagnosis of dementia requires a number of established features that are present when the disease is fully developed, but not always in the early stages, the need for a biological marker has proven to be urgent, in terms of both diagnosis and monitoring of AD. AD has been shown to affect peripheral blood mononuclear cells (PBMCs) that are a critical component of the immune system which provide defence against infection. Although studies are continuously supplying additional data that emphasize the central role of inflammation in AD, PBMCs have not been sufficiently investigated in this context. Delineating biochemical alterations in AD blood constituents may prove valuable in identifying accessible footprints that reflect degenerative processes within the Central Nervous System (CNS). In this review, we address the role of biomarkers in AD with a focus on the notion that PBMCs may serve as a peripheral laboratory to find molecular signatures that could aid in differential diagnosis with other forms of dementia and in monitoring of disease progression.
    BioMed Research International 04/2014; 2014:169203. DOI:10.1155/2014/169203 · 2.71 Impact Factor
  • Source
    • "These data concur with previous reports of an ADassociated reduction in 5-hmC in the hippocampus (Chouliaras et al., 2013). Although there was a regional difference in 5-fC levels, no AD-associated changes in 5-mC, 5-fC, or 5-caC were observed, although previous reports have shown decrements in 5-mC in AD EC and hippocampus (Chouliaras et al., 2013; Mastroeni et al., 2010). Given the relatively small numbers of samples assessed in this study, further research investigating the specificity of the differences in 5-hmC and 5-fC, we report, particularly across different neuron and glia subtypes, will be of particular interest to the field. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Epigenetic processes play a key role in the central nervous system and altered levels of 5-methylcytosine have been associated with a number of neurologic phenotypes, including Alzheimer's disease (AD). Recently, 3 additional cytosine modifications have been identified (5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine), which are thought to be intermediate steps in the demethylation of 5-methylcytosine to unmodified cytosine. Little is known about the frequency of these modifications in the human brain during health or disease. In this study, we used immunofluorescence to confirm the presence of each modification in human brain and investigate their cross-tissue abundance in AD patients and elderly control samples. We identify a significant AD-associated decrease in global 5-hydroxymethylcytosine in entorhinal cortex and cerebellum, and differences in 5-formylcytosine levels between brain regions. Our study further implicates a role for epigenetic alterations in AD.
    Neurobiology of aging 02/2014; 35(8). DOI:10.1016/j.neurobiolaging.2014.02.002 · 4.85 Impact Factor
Show more